90,053 Shares in Twist Bioscience Corporation $TWST Acquired by Deutsche Bank AG

Key Points

• Deutsche Bank acquired 90,053 shares of Twist Bioscience in the second quarter, valued at approximately $9.3 million and representing about 0.14% of the company.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $98.30, despite the stock opening at $145.59.
• Twist’s quarterly revenue rose 23.2% year over year to $118.38 million, but its adjusted loss of $0.56 per share missed expectations; insiders also sold approximately $17.7 million of shares during the quarter.

Deutsche Bank AG acquired a new stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 90,053 shares of the company's stock, valued at approximately $9,265,000. Deutsche Bank AG owned about 0.14% of Twist Bioscience at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Quarry LP bought a new stake in shares of Twist Bioscience during the third quarter worth $28,000. Western Wealth Management LLC bought a new position in shares of Twist Bioscience in the 1st quarter valued at $31,000. Strs Ohio bought a new position in shares of Twist Bioscience in the 1st quarter valued at $33,000. Strategic Advocates LLC boosted its holdings in shares of Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company's stock valued at $34,000 after acquiring an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its holdings in shares of Twist Bioscience by 68.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company's stock valued at $44,000 after acquiring an additional 571 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TWST. Guggenheim boosted their price objective on Twist Bioscience from $60.00 to $107.00 and gave the stock a "buy" rating in a research report on Monday, June 29th. Evercore downgraded Twist Bioscience from an "outperform" rating to an "in-line" rating and set a $102.00 target price for the company. in a research report on Monday, July 6th. Barclays lifted their price target on Twist Bioscience from $65.00 to $95.00 and gave the company an "overweight" rating in a research note on Wednesday, June 24th. UBS Group set a $89.00 price target on Twist Bioscience in a report on Monday, June 15th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $98.30.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $145.59 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $145.93. The firm has a market cap of $9.13 billion, a PE ratio of -65.58 and a beta of 2.14. The firm's fifty day moving average is $100.69 and its 200-day moving average is $70.50.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.05). The company had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business's revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.33 earnings per share. Sell-side analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Buying and Selling

In other Twist Bioscience news, insider Dennis Cho sold 14,205 shares of the company's stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total value of $1,274,898.75. Following the sale, the insider owned 105,141 shares in the company, valued at approximately $9,436,404.75. The trade was a 11.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Emily M. Leproust sold 113,318 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $125.16, for a total value of $14,182,880.88. Following the completion of the sale, the chief executive officer directly owned 818,938 shares of the company's stock, valued at approximately $102,498,280.08. The trade was a 12.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 151,529 shares of company stock worth $17,708,772. Corporate insiders own 3.08% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source